Previous studies have been reported that inhibition of PARP1 leads to synthetic lethality in some BRCA1/2 mutant cancers (including ovarian and breast cancer), which could be specifically targeted by PARP1 inhibitors13. This evidence concerns the gene PARP1 and cancer.